Combining Low-Dose Rituximab and Bortezomib as Immunosuppressive Therapy for Acquired Hemophilia A: 6 Case Series

Acquired hemophilia A (AHA) is a rare bleeding disorder caused by autoantibodies against factor VIII. Persistently positive inhibitor titers increase the risk of bleeding. Upfront combined regimen with multiple mechanisms has the potential to shorten remission time to lower bleeding risk and reduce...

Descripción completa

Detalles Bibliográficos
Autores principales: Fu, Yuhan, Chen, Shu, Wang, Anzi, Luo, Jingyuan, Li, Qing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer India 2023
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10214338/
https://www.ncbi.nlm.nih.gov/pubmed/37362404
http://dx.doi.org/10.1007/s12288-023-01657-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10214338/
https://www.ncbi.nlm.nih.gov/pubmed/37362404
http://dx.doi.org/10.1007/s12288-023-01657-y

Ejemplares similares